Clinical Trials in Progress, Bladder Cancer
Sunday, May 5, 2024 10:00 AM to 12:00 PM · 2 hr. (US/Central)
Learning Lab
Forum
Sunday, May 5
A Phase 2/3 Multicenter Trial Evaluating the Safety and Efficacy of ST-02 (Mucoadhesive Gemcitabine Suspension) for Ablation of Upper Tract Urothelial Carcinoma
Sunday, May 5, 2024 10:00 AM to 10:08 AM
Learning Lab
A Randomized Trial of Apalutamide in Non-Muscle Invasive Bladder Cancer (NCI INT 22-09-01)*
Sunday, May 5, 2024 10:08 AM to 10:16 AM
Learning Lab
MoonRISe-1: Phase 3 study of TAR-210, an erdafitinib intravesical delivery system, versus intravesical chemotherapy in patients with intermediate-risk non–muscle-invasive bladder cancer with susceptible FGFR alterations
Sunday, May 5, 2024 10:16 AM to 10:24 AM
Learning Lab
PIVOT-006: A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer Following Transurethral Resection of Bladder Tumor
Sunday, May 5, 2024 10:24 AM to 10:32 AM
Learning Lab
QUILT-2.005: A comparison of intravesical Bacillus Calmette-Guerin (BCG) in combination with the IL-15 superagonist N-803 to BCG alone in patients with BCG-naïve NMIBC
Sunday, May 5, 2024 10:32 AM to 10:40 AM
Learning Lab
SunRISe-3: TAR-200 plus cetrelimab or TAR-200 versus intravesical Bacillus Calmette–Guérin in patients with Bacillus Calmette–Guérin-naive high-risk non–muscle-invasive bladder cancer
Sunday, May 5, 2024 10:40 AM to 10:48 AM
Learning Lab
Bacillus Calmette-Guérin Plus Pembrolizumab Versus Bacillus Calmette-Guérin Alone for High-Risk Non–Muscle-Invasive Bladder Cancer That Persists/Recurs After Bacillus Calmette-Guérin Induction: Cohort A of the Phase 3 KEYNOTE-676 Study
Sunday, May 5, 2024 10:48 AM to 10:56 AM
Learning Lab
BOND-003- Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Sunday, May 5, 2024 10:56 AM to 11:04 AM
Learning Lab
SunRISe-5: A phase 3, randomized, open-label study of TAR-200 compared with intravesical chemotherapy after bacillus Calmette-Guérin in recurrent high-risk non–muscle-invasive bladder cancer
Sunday, May 5, 2024 11:04 AM to 11:12 AM
Learning Lab
A phase III, single-arm study to evaluate the efficacy and safety of paclitaxel-hyaluronic acid conjugate administered intravesically to patients with BCG-unresponsive Carcinoma in Situ of the bladder with or without Ta-T1 papillary disease (Orion-BC stud
Sunday, May 5, 2024 11:12 AM to 11:20 AM
Learning Lab
A Phase II prospective, open-label, multi-center, single arm study of Sasanlimab plus Sacituzumab Govitecan in BCG-unresponsive non-muscle invasive bladder cancer patients. SSANTROP (APRO07-2022)
Sunday, May 5, 2024 11:20 AM to 11:28 AM
Learning Lab
SunRISe-2: A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus chemoradiotherapy in patients with muscle-invasive bladder cancer
Sunday, May 5, 2024 11:28 AM to 11:36 AM
Learning Lab
Pembrolizumab Plus Chemoradiotherapy Versus Placebo Plus Chemoradiotherapy in Patients With Muscle-Invasive Bladder Cancer: Phase 3 KEYNOTE-992
Sunday, May 5, 2024 11:36 AM to 11:44 AM
Learning Lab
The “Get Moving Trial”: A Phase I/II RCT of Home-Based (P)Rehabilitation ((P)REHAB) with ExerciseRx in Muscle-Invasive Bladder Cancer (MIBC): Study protocol for a Randomized Controlled Trial
Sunday, May 5, 2024 11:44 AM to 11:52 AM
Learning Lab
Comparison of Apixaban versus Enoxaparin for VTE Prevention After Radical Cystectomy; The CARE Trial
Sunday, May 5, 2024 11:52 AM to 12:00 PM
Learning Lab
